Cargando…

Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization

OBJECTIVE: Statins pleiotropically provide additional benefits in reducing atherosclerosis, but their effects on intraplaque angiogenesis (IPA) and hemorrhage (IPH) remain unclear. Therefore, we discriminated statin’s lipid-lowering dependent and independent effects on IPA and IPH. APPROACH AND RESU...

Descripción completa

Detalles Bibliográficos
Autores principales: Baganha, Fabiana, de Jong, Rob C. M., Peters, Erna A., Voorham, Wietske, Jukema, J. Wouter, Delibegovic, Mirela, de Vries, Margreet R., Quax, Paul H. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292290/
https://www.ncbi.nlm.nih.gov/pubmed/33550461
http://dx.doi.org/10.1007/s10456-021-09767-9
_version_ 1783724800880934912
author Baganha, Fabiana
de Jong, Rob C. M.
Peters, Erna A.
Voorham, Wietske
Jukema, J. Wouter
Delibegovic, Mirela
de Vries, Margreet R.
Quax, Paul H. A.
author_facet Baganha, Fabiana
de Jong, Rob C. M.
Peters, Erna A.
Voorham, Wietske
Jukema, J. Wouter
Delibegovic, Mirela
de Vries, Margreet R.
Quax, Paul H. A.
author_sort Baganha, Fabiana
collection PubMed
description OBJECTIVE: Statins pleiotropically provide additional benefits in reducing atherosclerosis, but their effects on intraplaque angiogenesis (IPA) and hemorrhage (IPH) remain unclear. Therefore, we discriminated statin’s lipid-lowering dependent and independent effects on IPA and IPH. APPROACH AND RESULTS: ApoE3*Leiden mice are statin-responsive due to ApoE and LDLR presence, but also allow to titrate plasma cholesterol levels by diet. Therefore, ApoE3*Leiden mice were fed a high-cholesterol-inducing-diet (HCD) with or without atorvastatin (A) or a moderate-cholesterol-inducing-diet (MCD). Mice underwent vein graft surgery to induce lesions with IPA and IPH. Cholesterol levels were significantly reduced in MCD (56%) and HCD + A (39%) compared to HCD with no significant differences between MCD and HCD + A. Both MCD and HCD + A have a similar reduction in vessel remodeling and inflammation comparing to HCD. IPA was significantly decreased by 30% in HCD + A compared to HCD or MCD. Atorvastatin treatment reduced the presence of immature vessels by 34% vs. HCD and by 25% vs. MCD, resulting in a significant reduction of IPH. Atorvastatin’s anti-angiogenic capacity was further illustrated by a dose-dependent reduction of ECs proliferation and migration. Cultured mouse aortic-segments lost sprouting capacity upon atorvastatin treatment and became 30% richer in VE-Cadherin expression and pericyte coverage. Moreover, Atorvastatin inhibited ANGPT2 release and decreased VE-Cadherin(Y685)-phosphorylation in ECs. CONCLUSIONS: Atorvastatin has beneficial effects on vessel remodeling due to its lipid-lowering capacity. Atorvastatin has strong pleiotropic effects on IPA by decreasing the number of neovessels and on IPH by increasing vessel maturation. Atorvastatin improves vessel maturation by inhibiting ANGPT2 release and phospho(Y658)-mediated VE-Cadherin internalization.
format Online
Article
Text
id pubmed-8292290
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-82922902021-07-23 Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization Baganha, Fabiana de Jong, Rob C. M. Peters, Erna A. Voorham, Wietske Jukema, J. Wouter Delibegovic, Mirela de Vries, Margreet R. Quax, Paul H. A. Angiogenesis Original Paper OBJECTIVE: Statins pleiotropically provide additional benefits in reducing atherosclerosis, but their effects on intraplaque angiogenesis (IPA) and hemorrhage (IPH) remain unclear. Therefore, we discriminated statin’s lipid-lowering dependent and independent effects on IPA and IPH. APPROACH AND RESULTS: ApoE3*Leiden mice are statin-responsive due to ApoE and LDLR presence, but also allow to titrate plasma cholesterol levels by diet. Therefore, ApoE3*Leiden mice were fed a high-cholesterol-inducing-diet (HCD) with or without atorvastatin (A) or a moderate-cholesterol-inducing-diet (MCD). Mice underwent vein graft surgery to induce lesions with IPA and IPH. Cholesterol levels were significantly reduced in MCD (56%) and HCD + A (39%) compared to HCD with no significant differences between MCD and HCD + A. Both MCD and HCD + A have a similar reduction in vessel remodeling and inflammation comparing to HCD. IPA was significantly decreased by 30% in HCD + A compared to HCD or MCD. Atorvastatin treatment reduced the presence of immature vessels by 34% vs. HCD and by 25% vs. MCD, resulting in a significant reduction of IPH. Atorvastatin’s anti-angiogenic capacity was further illustrated by a dose-dependent reduction of ECs proliferation and migration. Cultured mouse aortic-segments lost sprouting capacity upon atorvastatin treatment and became 30% richer in VE-Cadherin expression and pericyte coverage. Moreover, Atorvastatin inhibited ANGPT2 release and decreased VE-Cadherin(Y685)-phosphorylation in ECs. CONCLUSIONS: Atorvastatin has beneficial effects on vessel remodeling due to its lipid-lowering capacity. Atorvastatin has strong pleiotropic effects on IPA by decreasing the number of neovessels and on IPH by increasing vessel maturation. Atorvastatin improves vessel maturation by inhibiting ANGPT2 release and phospho(Y658)-mediated VE-Cadherin internalization. Springer Netherlands 2021-02-07 2021 /pmc/articles/PMC8292290/ /pubmed/33550461 http://dx.doi.org/10.1007/s10456-021-09767-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Baganha, Fabiana
de Jong, Rob C. M.
Peters, Erna A.
Voorham, Wietske
Jukema, J. Wouter
Delibegovic, Mirela
de Vries, Margreet R.
Quax, Paul H. A.
Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization
title Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization
title_full Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization
title_fullStr Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization
title_full_unstemmed Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization
title_short Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization
title_sort atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting angpt2 release and ve-cadherin internalization
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292290/
https://www.ncbi.nlm.nih.gov/pubmed/33550461
http://dx.doi.org/10.1007/s10456-021-09767-9
work_keys_str_mv AT baganhafabiana atorvastatinpleiotropicallydecreasesintraplaqueangiogenesisandintraplaquehaemorrhagebyinhibitingangpt2releaseandvecadherininternalization
AT dejongrobcm atorvastatinpleiotropicallydecreasesintraplaqueangiogenesisandintraplaquehaemorrhagebyinhibitingangpt2releaseandvecadherininternalization
AT petersernaa atorvastatinpleiotropicallydecreasesintraplaqueangiogenesisandintraplaquehaemorrhagebyinhibitingangpt2releaseandvecadherininternalization
AT voorhamwietske atorvastatinpleiotropicallydecreasesintraplaqueangiogenesisandintraplaquehaemorrhagebyinhibitingangpt2releaseandvecadherininternalization
AT jukemajwouter atorvastatinpleiotropicallydecreasesintraplaqueangiogenesisandintraplaquehaemorrhagebyinhibitingangpt2releaseandvecadherininternalization
AT delibegovicmirela atorvastatinpleiotropicallydecreasesintraplaqueangiogenesisandintraplaquehaemorrhagebyinhibitingangpt2releaseandvecadherininternalization
AT devriesmargreetr atorvastatinpleiotropicallydecreasesintraplaqueangiogenesisandintraplaquehaemorrhagebyinhibitingangpt2releaseandvecadherininternalization
AT quaxpaulha atorvastatinpleiotropicallydecreasesintraplaqueangiogenesisandintraplaquehaemorrhagebyinhibitingangpt2releaseandvecadherininternalization